AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06428409
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks
Trial: NCT06428409
Drug: Leucovorin (LV) or levoleucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV or levoleucovorin is administered by IV infusion every 2 weeks
Trial: NCT06428409
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Trial: NCT06428409
Drug: Supportive care measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Trial: NCT06369285
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter
Trial: NCT06172296
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06172296
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06738407
Drug: Doxycycline hyclate delayed released 200 mg
RxNorm normalized name: doxycycline hyclate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.
Trial: NCT06738407
Drug: Doxycycline hyclate delayed released 200 mg weekly
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline taken by mouth weekly regardless of sexual activity
Trial: NCT06786650
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
Trial: NCT06356129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06356129
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06356129
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05610735
Drug: Withaferin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha in the form of tablets will be administered orally on daily basis.
Trial: NCT05610735
Drug: Ashwagandha
RxNorm normalized name: Ashwagandha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally on daily basis twice a day
Trial: NCT05610735
Drug: Combination of ASWD and DOXIL
RxNorm normalized name: combinations of levothyroxine and liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
Trial: NCT06750094
Drug: Leucovorin calcium/Levoleucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Trial: NCT05844501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo orally twice daily for 28 days
Trial: NCT06503146
Drug: [18F]FAPI-74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
Trial: NCT06503146
Drug: [18F]FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
Trial: NCT06516952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06120140
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline tablet will be administered orally.
Trial: NCT06120140
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline capsule will be administered orally.
Trial: NCT06120140
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin lotion will be used as topical application on the scalp.
Trial: NCT04858334
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06435429
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT06741969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC.
Trial: NCT06741969
Drug: Standard of care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-defined topical and systemic standard of care background treatments.
Trial: NCT06578247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo at 60 mg/day orally once daily
Trial: NCT06578247
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Trial: NCT05784688
Drug: TU2218 + KEYTRUDA® (Pembrolizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered
Trial: NCT04821271
Drug: TS-161 (50 - 100 mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 and 2 Experimental Intervention
Trial: NCT06214858
Drug: SHEN211 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
Trial: NCT05550714
Drug: general anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
Trial: NCT05550714
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
Trial: NCT06530524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline into the at-risk major salivary glands
Trial: NCT05157685
Drug: Azithromycin Oral Tablet
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
Trial: NCT05157685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
Trial: NCT05999708
Drug: GSK4381406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4381406 will be administered.
Trial: NCT05999708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT05999708
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin will be administered.
Trial: NCT05751668
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05121051
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06621576
Drug: HM2002 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
Trial: NCT06179160
Drug: INCB161734
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB161734 will be administered at protocol defined dose.
Trial: NCT06179160
Drug: GEMNabP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMNabP will be administered at protocol defined dose.
Trial: NCT06179160
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX will be administered at protocol defined dose.
Trial: NCT06548360
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Trial: NCT06757010
Drug: NE3107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE3107 20 mg BID
Trial: NCT06757010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT06500884
Drug: Prophylaxis B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis B will be administered orally.
Trial: NCT06500884
Drug: Prophylaxis C
RxNorm normalized name: HERBAL STONE PROPHYLAXIS CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis C will be administered orally.
Trial: NCT06425159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once daily
Trial: NCT06667700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Trial: NCT06325293
Drug: Azithromycin Pfizer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
Trial: NCT06325293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control comparator arm: 5 days of placebo
Trial: NCT05672459
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT04301076
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04301076
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01471925
Drug: Nexium®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days.
Trial: NCT06318442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT04932005
Drug: DZD2269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
Trial: NCT04932005
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
Trial: NCT04859439
Drug: DBPR108 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DBPR108, tablet, oral
Trial: NCT05915728
Drug: Gadoquatrane (BAY1747846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Trial: NCT06456099
Drug: Ultrasound-guided corticosteroid injection
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
Trial: NCT04529265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal volume of normal saline after induction of anesthesia and at the end of surgery
Trial: NCT05511558
Drug: [14C]-Fosgonimeton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon-14 Radiolabeled Fosgonimeton
Trial: NCT05110599
Drug: Bryophyllum 50% chewable tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
Trial: NCT05825560
Drug: OFA multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal opioid free analgesia
Trial: NCT05825560
Drug: Standard multimodal analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard remifentanil analgesia
Trial: NCT05244811
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of progestin in treatment of ovarian cystn
Trial: NCT02154347
Drug: KAD-1229
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02154347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05089981
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous use of N acetyl cysteine in prescribed doses
Trial: NCT05089981
Drug: Placebo of N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
Trial: NCT05459220
Drug: SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 Injection（Low Dose）
Trial: NCT05459220
Drug: SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 Injection（High Dose）
Trial: NCT05459220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for SHR0410 Injection.
Trial: NCT06414512
Drug: AMBITION trial control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
Trial: NCT05647551
Drug: BOTOX®/VISTABEL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial Injection
Trial: NCT05982080
Drug: FP002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
Trial: NCT06539507
Drug: BCX17725
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX17725 for injection
Trial: NCT06539507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for injection
Trial: NCT04930237
Drug: Relistor Injectable Product
RxNorm normalized name: Relistor Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
Trial: NCT04732429
Drug: HST5040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid solution
Trial: NCT04732429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid solution
Trial: NCT04925674
Drug: HEC53856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.
Trial: NCT05583214
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be given IV stat to the group after induction of spinal anesthesia
Trial: NCT06450574
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Trial: NCT04678908
Drug: HB0025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
Trial: NCT04692376
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
Trial: NCT05550597
Drug: Fentanyl HCl
RxNorm normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
Trial: NCT04791202
Drug: Methylprednisolone Acetate 40 MG/ML
RxNorm normalized name: methylprednisolone acetate 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm descriptions
Trial: NCT06163352
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
Trial: NCT05238155
Drug: antimetabolite
RxNorm normalized name: Antimetabolite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
Trial: NCT05411874
Drug: HD-DXM
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg po qd for 4days
Trial: NCT06160622
Drug: Leritrelvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05199441
Drug: Control group placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group takes 1,500 mg/day of placebo for 8 weeks.
Trial: NCT04488003
Drug: Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).